TP53 and B-cell chronic lymphocytic leukemia: Disruption of TP53, through mutation and/or deletion, can either be already present in the CLL phase prior to treatment requirement (in 10–15% of the cases), representing an independent risk factor of DLBCL-type RT development, or can also be acquired at the time of transformation (Figure 1) [46,47].